Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 19470620)

1.

Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M.

J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72. doi: 10.1210/jc.2008-2640. Epub 2009 May 26.

2.

Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.

Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP.

J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8. Epub 2007 Jul 31.

PMID:
17666472
3.

Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.

Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, Viccica G, Pinchera A, Marcocci C.

J Endocrinol Invest. 2012 Jul;35(7):655-60. doi: 10.3275/7970. Epub 2011 Sep 30.

PMID:
21971564
4.

Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D.

J Clin Endocrinol Metab. 2011 Jan;96(1):E9-18. doi: 10.1210/jc.2010-1221. Epub 2010 Oct 13.

5.

Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.

Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D.

J Clin Endocrinol Metab. 2009 Dec;94(12):4860-7. doi: 10.1210/jc.2009-1472. Epub 2009 Oct 16.

PMID:
19837909
6.

Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.

Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Tóth M.

Eur J Endocrinol. 2015 May;172(5):527-35. doi: 10.1530/EJE-14-0877. Epub 2015 Jan 30.

PMID:
25637076
7.

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D.

J Clin Endocrinol Metab. 2005 Jan;90(1):135-41. Epub 2004 Nov 2.

PMID:
15522938
8.

[Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].

Arranz Martín A, Azcárate Villalón A, Luque Ramírez M, Santana Durán B, Marazuela Azpíroz M, Paniagua Ruiz A, Carraro R, Gómez Pan A.

Endocrinol Nutr. 2011 Jan;58(1):24-31. doi: 10.1016/j.endonu.2010.09.009. Spanish.

PMID:
21277266
9.

Cinacalcet for the treatment of primary hyperparathyroidism.

Sajid-Crockett S, Singer FR, Hershman JM.

Metabolism. 2008 Apr;57(4):517-21. doi: 10.1016/j.metabol.2007.11.014.

PMID:
18328354
10.

Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.

Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A.

Minerva Endocrinol. 2013 Dec;38(4):389-94.

PMID:
24285106
11.

Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group.

Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, Minisola S, Frasoldati A, Papini E, Scillitani A, Banti C, Del Prete M, Vescini F, Gianotti L, Cavalli L, Romagnoli E, Colao A, Cetani F, Marcocci C.

Clin Endocrinol (Oxf). 2013 Jul;79(1):20-6. doi: 10.1111/cen.12108. Epub 2013 Apr 27.

PMID:
23228121
12.

Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.

Dong BJ.

Clin Ther. 2005 Nov;27(11):1725-51. Review.

PMID:
16368445
13.

Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.

Norman J, Lopez J, Politz D.

Ann Surg Oncol. 2012 May;19(5):1466-71. doi: 10.1245/s10434-011-2065-9. Epub 2011 Sep 16.

PMID:
21922336
14.

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.

Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA.

Am J Kidney Dis. 2009 Feb;53(2):197-207. doi: 10.1053/j.ajkd.2008.09.021. Epub 2008 Dec 24.

PMID:
19110359
15.

Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.

St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA.

Clin J Am Soc Nephrol. 2009 Feb;4(2):354-60. doi: 10.2215/CJN.05241008. Epub 2009 Jan 7.

16.

Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.

Iglesias P, Ais G, González A, Tajada P, García Arévalo C, Fernández Pardo E, Díez JJ.

Am J Med Sci. 2008 Feb;335(2):111-4. doi: 10.1097/MAJ.0b013e3181379f3e.

PMID:
18277118
17.

Update on the use of cinacalcet in the management of primary hyperparathyroidism.

Marcocci C, Cetani F.

J Endocrinol Invest. 2012 Jan;35(1):90-5. doi: 10.3275/8112. Epub 2011 Nov 21. Review.

PMID:
22104762
18.

The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.

Schwarz P, Body JJ, Cáp J, Hofbauer LC, Farouk M, Gessl A, Kuhn JM, Marcocci C, Mattin C, Muñoz Torres M, Payer J, Van De Ven A, Yavropoulou M, Selby P.

Eur J Endocrinol. 2014 Dec;171(6):727-35. doi: 10.1530/EJE-14-0355. Epub 2014 Sep 20.

PMID:
25240499
19.

MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.

Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S, Persani L, Beck-Peccoz P, Spada A.

Eur J Endocrinol. 2012 Aug;167(2):157-64. doi: 10.1530/EJE-12-0117. Epub 2012 May 10.

20.

Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Duntas LH, Stathatos N.

Endocrine. 2011 Jun;39(3):199-204. doi: 10.1007/s12020-011-9452-7. Epub 2011 Mar 26. Review.

PMID:
21442382
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk